Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom

Journal of the European Academy of Dermatology and Venereology : JEADV
R B WarrenD McBride

Abstract

Psoriasis causes work productivity impairment that increases with disease severity. Whether differential treatment efficacy translates into differential indirect cost savings is unknown. To assess work hours lost and indirect costs associated with secukinumab versus ustekinumab and etanercept in the United Kingdom (UK). This was a post hoc analysis of work impairment data collected in the CLEAR study (secukinumab vs. ustekinumab) and applied to the FIXTURE study (secukinumab vs. etanercept). Weighted weekly and annual average indirect costs per patient per treatment were calculated from (i) overall work impairment derived from Work Productivity and Activity Impairment data collected in CLEAR at 16 and 52 weeks by Psoriasis Area and Severity Index (PASI) response level; (ii) weekly/annual work productivity loss by PASI response level; (iii) weekly and annual indirect costs by PASI response level, based on hours of work productivity loss; and (iv) weighted average indirect costs for each treatment. In the primary analysis, work impairment data for employed patients in CLEAR at Week 16 were used to compare secukinumab and ustekinumab. Secondary analyses were conducted at different time points and with patient cohorts, including FI...Continue Reading

References

Oct 9, 1996·JAMA : the Journal of the American Medical Association·L B RussellM C Weinstein
Feb 15, 2005·Annals of the Rheumatic Diseases·S R Feldman, G G Krueger
Dec 21, 2005·Archives of Dermatology·Joel M GelfandDavid J Margolis
Aug 12, 2006·Dermatology : International Journal for Clinical and Investigative Dermatology·Jochen M Schmitt, Daniel E Ford
Oct 15, 2009·American Journal of Clinical Dermatology·Ying WuMohan Bala
Mar 20, 2010·Journal of the European Academy of Dermatology and Venereology : JEADV·N MeyerJ P Ortonne
Sep 28, 2012·The Journal of Investigative Dermatology·Rosa ParisiUNKNOWN Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team
Jul 10, 2014·The New England Journal of Medicine·Richard G LangleyUNKNOWN FIXTURE Study Group
Jul 24, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Steven R FeldmanUsha G Mallya
Nov 6, 2014·Journal of the European Academy of Dermatology and Venereology : JEADV·L Puig
Apr 18, 2015·Journal of the American Academy of Dermatology·Jacqueline Vanderpuye-OrgleMark Lebwohl
Aug 9, 2015·Journal of the American Academy of Dermatology·Caroline P SchaeferCarla Mamolo
Oct 21, 2015·Journal of the European Academy of Dermatology and Venereology : JEADV·A NastN Yawalkar
Nov 5, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·C N GrahamP Mollon
Jun 19, 2016·Actas dermo-sifiliográficas·R Burgos-PolM Á Casado
May 18, 2017·The British Journal of Dermatology·C H SmithM F Mohd Mustapa

❮ Previous
Next ❯

Software Mentioned

FIXTURE
CLEAR

Related Concepts

Related Feeds

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.